GUTS news

Fractyl Health will advance its Revita therapy toward an FDA De Novo submission based on positive clinical data while discontinuing its Rejuva gene therapy. This strategic shift includes a workforce reduction to extend cash runway into 2027.

Fractyl Health announced topline 6-month data showing Revita maintained 80% of GLP-1 induced weight loss versus 67% in sham controls. This neuroendocrine intervention offers a new therapeutic option in the weight maintenance market following GLP-1 discontinuation.

Fractyl Health announced positive one-year results from its REVEAL-1 open-label study showing patients maintained approximately 78% of GLP-1-induced weight loss after a single Revita procedure and GLP-1 discontinuation. The results position Revita as a potential procedural therapy for post-GLP-1 wei…